Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study

BACKGROUND/AIM: Studies regarding effectiveness of anakinra and tocilizumab treatments in coronavirus disease 2019 (COVID-19) have contradictory results. Furthermore, there is scarce comparative data regarding superiority of any agent. To further elucidate any superiority between these two agents, w...

Descripción completa

Detalles Bibliográficos
Autores principales: KÜÇÜKŞAHİN, Orhan, ERDEN, Abdulsamet, KARAKAŞ, Özlem, GÜVEN, Serdar Can, ARMAĞAN, Berkan, ŞAHİNER, Enes Seyda, İNAN, Osman, KURTİPEK, Ali Can, GEMCİOĞLU, Emin, KARAAHMETOĞLU, Selma, TURAN, Sema, İZDEŞ, Seval, ERDEM, Deniz, AYPAK, Adalet, AYHAN, Müge, AKINCI, Esragül, BODUR, Hürrem, GÜNER, Rahmet, OMMA, Ahmet, ATEŞ, İhsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific and Technological Research Council of Turkey (TUBITAK) 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395730/
https://www.ncbi.nlm.nih.gov/pubmed/36422492
http://dx.doi.org/10.55730/1300-0144.5487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395730/
https://www.ncbi.nlm.nih.gov/pubmed/36422492
http://dx.doi.org/10.55730/1300-0144.5487

Ejemplares similares